Koers XTL Biopharmaceuticals Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
XTLB
IL0010854979
Biotechnologie & Medisch Onderzoek
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 6,36 mln. 23,73 mln. 5,97 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | - 0 0 | Nettowinst (verlies) 2022 | -1 mln. -3,73 mln. -938K | EV/omzet 2021 | - |
Nettoliquiditeiten 2021 | 6,13 mln. 22,85 mln. 5,75 mln. | Nettoliquiditeiten 2022 | 3,72 mln. 13,88 mln. 3,49 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
39,2
x | K/w-verhouding 2022 |
-4,72
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 93,3% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30-12-14 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 01-01-99 |
Doron Turgeman
CHM | Chairman | 56 | 30-12-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30-12-14 |
Director/Board Member | 57 | 29-01-20 | |
Director/Board Member | 53 | 01-04-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,17% | 42,19 mld. | |
+10,92% | 42,24 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+5,23% | 24,63 mld. | |
-24,79% | 18,2 mld. | |
+26,69% | 12,01 mld. | |
-3,13% | 11,76 mld. | |
+6,57% | 10,4 mld. |